The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events than standard therapy.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/new-egfr-lung-cancer-drug-nears-eu-approval-2025a1000z55?src=rss
Author :
Publish date : 2025-12-15 14:59:00
Copyright for syndicated content belongs to the linked Source.